Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NICE (National Institute for Health and Clinical Excellence) set to retain home vs hospital haemodialysis policy - "no new data?":

This article was originally published in Clinica

Executive Summary

The UK's National Institute for Health and Clinical Excellence (NICE) is proposing that its current policy on home versus hospital haemodialysis remain unaltered, in view of an apparent lack of new evidence. In a re-run of the search used in the original assessment, NICE has found insufficient additional data to merit carrying out the three-year review, now due, but is asking all original consultees to confirm whether or not any such evidence might exist. In the current October 2002 guidance, NICE recommended that patients in England and Wales with end-stage renal disease who are suitable for home dialysis should be offered the choice between receiving their haemodialysis at home or in a hospital/satellite unit, wherever they live.

You may also be interested in...



COVID-19 Vaccine 'Brexit Bonus' A Myth

The Pink Sheet explains the procedures underpinning the UK’s emergency use authorization of the Pfizer/BioNTech COVID-19 vaccine.

Warning Letter Close-Outs – November 2020

The US Food and Drug Administration posted two device-related closeout letters in November.

Jazz And PharmaMar’s Zepzelca Hits Buffers In ATLANTIS Study

Jazz and PharmaMar need to see what further data will be needed to convert their FDA authorization into a full approval following disappointing results in the ATLANTIS Phase III trial.

Topics

UsernamePublicRestriction

Register

OM006664

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel